HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Johns Hopkins Center Receives Five-Year, $8 Mil. NCCAM Grant

This article was originally published in The Tan Sheet

Executive Summary

A new complementary medicine center at Johns Hopkins University initially will concentrate on alternative therapies for breast and prostate cancer.

You may also be interested in...



CAM Cancer Research Targeted In NCCAM-NCI Program Announcement

NCCAM and the National Cancer Institute issued a program announcement Dec. 17 seeking to stimulate research into complementary and alternative cancer therapies

Chinese herbs and breast cancer

Sixteen of 69 traditional Chinese botanical and zoological remedies "exhibited pronounced effects (>75% growth inhibition) on at least one" of five breast cancer cell lines, Michael Campbell, et al., University of California-San Francisco, report at AACR meeting. "Future studies with these crude aqueous extracts may lead to the isolation of novel active anti-tumor compounds," researchers note in poster abstract. Johns Hopkins University is studying use of Chinese herbals in breast and prostate cancer treatment (1"The Tan Sheet" Oct. 9, 2000, p. 15)

Vitamin/Herb CAM Therapies Common Among Cancer Outpatients - Survey

Almost 63% of cancer outpatients surveyed who were familiar with vitamin/herb complementary and alternative medicine reported using the therapies, according to a study in the July issue of the Journal of Clinical Oncology.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS133753

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel